These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 2671473)

  • 1. Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.
    von der Leyen H
    Klin Wochenschr; 1989 Jun; 67(12):605-15. PubMed ID: 2671473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
    von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
    Lues I; Beier N; Jonas R; Klockow M; Haeusler G
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium.
    Böhm M; Morano I; Pieske B; Rüegg JC; Wankerl M; Zimmermann R; Erdmann E
    Circ Res; 1991 Mar; 68(3):689-701. PubMed ID: 1660359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts.
    Bethke T; Klimkiewicz A; Kohl C; von der Leyen H; Mehl H; Mende U; Meyer W; Neumann J; Schmitz W; Scholz H
    J Cardiovasc Pharmacol; 1991 Sep; 18(3):386-97. PubMed ID: 1720839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.
    Kelso EJ; McDermott BJ; Silke B
    Br J Pharmacol; 1993 Dec; 110(4):1387-94. PubMed ID: 8306078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.
    Wynne DG; Poole-Wilson PA; Harding SE
    Br J Pharmacol; 1993 Aug; 109(4):1071-8. PubMed ID: 7691363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
    Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
    Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evidence of positive inotropism of EMD 57033 through calcium sensitization.
    Haeusler G; Jonas R; Minck KO; Schliep HJ; Schelling P; Weygandt H; Lues I
    J Cardiovasc Pharmacol; 1997 May; 29(5):647-55. PubMed ID: 9213208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease.
    Osadchii OE
    Cardiovasc Drugs Ther; 2007 Jun; 21(3):171-94. PubMed ID: 17373584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase inhibition and Ca2+ sensitization.
    Ravens U; Himmel HM; Flüss M; Davia K; Harding SE
    Mol Cell Biochem; 1996 Apr 12-26; 157(1-2):245-9. PubMed ID: 8739254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of positive inotropic phosphodiesterase III inhibitors.
    Honerjäger P
    Eur Heart J; 1989 Aug; 10 Suppl C():25-31. PubMed ID: 2553411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced alpha 1- and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure.
    Steinfath M; Danielsen W; von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Reich T; Schmitz W; Scholz H
    Br J Pharmacol; 1992 Feb; 105(2):463-9. PubMed ID: 1348446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
    Ahn HS; Eardley D; Watkins R; Prioli N
    Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of the positive inotropic effect of phosphodiesterase inhibitors].
    Scholz H; Dieterich HA; Schmitz W
    Z Kardiol; 1991; 80 Suppl 4():1-6. PubMed ID: 1656618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
    Katano Y; Endoh M
    J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cardiotonic sodium channel activators by potassium depolarization in isolated guinea-pig atria.
    Berthold H; Scholtysik G; Schaad A
    J Pharmacol Methods; 1990 Sep; 24(2):121-35. PubMed ID: 1700227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase inhibition by naloxone augments the inotropic actions of beta-adrenergic stimulation.
    Park WK; Chang CH; Chae JE; Kim MH; Cho YL; Ahn DS
    Acta Anaesthesiol Scand; 2009 Sep; 53(8):1043-51. PubMed ID: 19572940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle.
    Silver PJ; Harris AL; Canniff PC; Lepore RE; Bentley RG; Hamel LT; Evans DB
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):530-40. PubMed ID: 2470989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of SCH00013: a novel Ca2+ sensitizer.
    Endoh M; Sugawara H; Mineshima M
    Cardiovasc Drug Rev; 2001; 19(4):345-66. PubMed ID: 11830752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.